Latest News

Interim Report and Half-Year Financial Results

Feb 25th, 2021

Starpharma today released its interim report and financial results for the half-year ended 31 December 2020.

Read More

VIRALEZE™ antiviral nasal spray registered in Europe

Feb 23rd, 2021

Starpharma announced today it had received confirmation that the VIRALEZE™ antiviral nasal spray has been successfully registered for sale in Europe, including in the UK.

Read More

Starpharma signs DEP® ADC Research Agreement with MSD

Feb 12th, 2021

Starpharma today announced that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth NJ USA. Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology.

 

Read More

AZD0466 clinical DEP® program global expansion

Feb 9th, 2021

Starpharma today announced that it had been advised by AstraZeneca of its intention to expand the clinical program for AZD0466 to include a multi-centre global Phase 1 study. The study will recruit patients with acute leukaemias.

Read More

In the media

Starpharma Up With News, Down With None; Timing Entry Makes Sense

Feb 25th, 2021

Seeking Alpha, a financial market portal featured an update Starpharma, including the European registration of its VIRALEZE™ antiviral nasal spray. To read the full article click here.

Read More

Channel 7 News reports Starpharma's VIRALEZE has been registered in the UK/Europe

Feb 23rd, 2021

Channel 7 News (Melbourne) reports Starpharma's VIRALEZE™ has been registered in the UK/Europe. Watch here

Read More

Starpharma signs research agreement with MSD

Feb 12th, 2021

The Market Herald reported that Starpharma signed a Research Agreement with Merck & Co., Inc., Kenilworth NJ USA for dendrimer-based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology. Read more here

Read More

Ausbiz interviews Starpharma CEO Dr Jackie Fairley

Feb 10th, 2021

Finance and market news website AusBiz interviewed Starpharma CEO Dr Jackie Fairley to discuss the global expansion of AstraZeneca’s clinical trial for AZD0466 and their multi-product DEP® licence with Starpharma. She also spoke about the upcoming launch of VIRALEZE in Europe. Watch the interview here.

 

Read More

Shareholder Updates

Shareholder Update October 2020

Oct 20th, 2020

In this issue:

>> Starpharma is expediting the development of the SPL7013 COVID‑19 nasal spray

>> Rapid progress in the DEP® irinotecan phase 2 & preparations underway for clinical combinations

>> DEP® irinotecan in combination with immuno-oncology showed superior performance in colon cancer models

>> VivaGel® BV launched in Central & Eastern Europe and Nordic region

>> Fleurstat BVgel gains expanded TGA approval to include prevention of recurrent Bacterial Vaginosis (BV) indication

>> VivaGel® BV has now been approved in 40 countries with further submissions underway

>> Starpharma awarded $1 million MRFF funding for COVID-19 nasal spray

>> DEP® docetaxel update & patient case study

>> DEP® cabazitaxel update & patient case study

>> Multiple DEP® products showcased at AACR 2020 Annual Meeting

>> New DEP® partnership signed with Chase Sun for anti-infective program

>> AstraZeneca’s AZD0466 trial opens at MD Anderson Cancer Center

>> Starpharma creates slow release soluble DEP® remdesivir

>> DEP® partnering, including Antibody Drug Conjugates

>> DEP® lutetium; impressive efficacy in human prostate cancer model

>> Outlook, Annual Report & ESG Report & recent news 

Read More

Shareholder Update May 2020

May 14th, 2020

In this issue:

>> VivaGel® BV launched in Asia

>> Fleurstat BVgel launched in NZ

>> DEP® irinotecan phase 2 commences after positive phase 1 results 

>> SPL7013 against SARS-COV-2 (coronavirus)

>> Fleurstat BVgel ranks as #1 topical BV treatment

>> Okamoto adds 11 more Asian countries to  licence

>> US regulatory update

>> COVID-19: Starpharma’s operations continue with minimal disruption

>> DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan 

>> DEP® patient case studies

>> AstraZeneca’s DEP® trial ongoing in the US & US$3 million milestone payment received

>> New DEP® ADC programs

>> DEP® pipeline targets multiple high-value areas

>> Other DEP® programs

>> Outlook, recent news & events

 

Read More

Sign up to receive news here